The first wave of Risperdal trials are slated to begin later this year and at the beginning of 2015 in Pennsylvania, where hundreds of claims over the antipsychotic medication have been consolidated in the Philadelphia Court of Common Pleas.

According to court records, the first bellwether trial is scheduled to begin on November 3rd, followed by a second on January 3, 2015 and a third in February 2015. It has not been disclosed which specific cases will serve in the trial program, but the chosen suits will undoubtedly include similar claims against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, who allegedly failed to properly warn patients about risks associated with the medication. One of these risks, plaintiffs assert, is gynecomastia, a condition categorized by male breast development that may result in breasts as large as D cups, creating the need for liposuction or a mastectomy to remove excess tissue that developed because of the drug. Men who are suffering from gynecomastia may experience swelling and tenderness in the breast, as well as other symptoms.

800 Court Records Now Included in Risperdal Litigation

Documents recently updated on the Philadelphia court’s website show 845 records now included in the Risperdal litigation, a number that has continued to increase over the past several months. These aren’t the only cases filed against the makers of this medication, however, as reports indicate that Johnson & Johnson and Janssen have been quietly settling lawsuits over Risperdal, a drug approved to treat adult and adolescent schizophrenia and bipolar disorder, for the past few years.

In September 2012, an article from Bloomberg.com noted the manufacturers’ settlement of a case involving a 21-year old man who allegedly suffered severe psychological trauma and underwent breast removal surgery after taking Risperdal as a child. Cases filed on behalf of at least five other boys were resolved shortly after, reports indicate.

What is probably Johnson & Johnson’s largest settlement involving Risperdal occurred a year later, when the company agreed to settle claims from the U.S. Department of Justice that this and several other medications were promoted for uses not approved by the U.S. Food and Drug Administration (FDA). The settlement was reached in November 2013 for more than $2.2 billion.

Consider a Risperdal Lawsuit

Contact our Firm to learn about filing a Risperdal lawsuit at (877) 779-1414.

Published October 3, 2014 by